Evidence Grade A — Regulatory approved. 4391 published studies. 116 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Daptomycin (sold as Cubicin) is an intravenous antibiotic with a unique mechanism — it punches holes in bacterial cell membranes, killing them through a completely different pathway than vancomycin or other standard antibiotics. Given once daily, it is used for serious skin infections and bloodstream infections caused by gram-positive bacteria, including MRSA. One important limitation: it cannot be used for pneumonia because a natural substance in the lungs inactivates it.
Daptomycin is also known by these brand and alternate names:
4,391 published studies: 2651 human, 256 animal, 996 in-vitro, 659 reviews
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion.
A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Daptomycin has a remarkable calcium-dependent mechanism. In the presence of calcium, the drug changes shape to expose a fatty acid tail, which inserts into the bacterial membrane. Multiple daptomycin molecules then cluster together to form channels that allow potassium ions to rush out of the bacterium. This ion leakage collapses the electrical charge across the membrane, which halts DNA replication, RNA synthesis, and protein production simultaneously — a multi-target kill mechanism that makes resistance development difficult.
Daptomycin's clinical evidence comes from Phase III trials in skin infections and bloodstream infections including endocarditis (heart valve infection). In the bloodstream infection trial, daptomycin matched vancomycin's effectiveness while causing significantly fewer kidney problems (11% versus 26%). Muscle toxicity is a known risk, requiring weekly blood tests to monitor a muscle enzyme called creatine kinase. The drug has become an important alternative to vancomycin, particularly when vancomycin resistance or intolerance is a concern. High-dose strategies (above the standard approved dose) and combination approaches with other antibiotics are used in clinical practice for difficult-to-treat MRSA infections, though these strategies are based more on clinical experience than large randomised trials. Generic versions have made daptomycin more affordable.
PeptideTrace tracks 116 registered clinical trials for Daptomycin sourced from ClinicalTrials.gov.
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria
Antibiotic Impregnated Beads in Osteomyelitis
Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study
FDA ORIG 1
FDA SUPPL 1
EMA Marketing Authorisation
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 11
FDA SUPPL 14
FDA SUPPL 6
FDA SUPPL 19
FDA SUPPL 17
Health Canada Market Authorisation
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 2
FDA SUPPL 1
FDA SUPPL 3
FDA SUPPL 2
FDA SUPPL 7
FDA SUPPL 5
FDA SUPPL 3
FDA ORIG 1
FDA SUPPL 1
FDA ORIG 1
FDA SUPPL 3
FDA SUPPL 9
FDA SUPPL 7
FDA SUPPL 6
FDA SUPPL 11
FDA SUPPL 4
FDA SUPPL 6
Daptomycin is a cyclic lipodepsipeptide (13 amino acids, 10 in macrocyclic lactone ring) from Streptomyces roseosporus. MW 1,620.67 Da. Features C10 lipid tail, lactone ring, two nonproteinogenic amino acids, three D-amino acids, and L-ornithine. Ca2+-dependent mechanism. IV at 4 mg/kg QD (cSSSI) or 6 mg/kg QD (bacteremia/endocarditis). Half-life ~8-9 hours. Inactivated by pulmonary surfactant.
Ca2+ binding induces conformational change exposing C10 tail, enabling insertion into bacterial membranes in phosphatidylglycerol-dependent manner. Oligomerizes (~4 subunits), creating ion channels. K+ efflux collapses transmembrane potential, halting DNA/RNA/protein synthesis. Also inhibits lipoteichoic acid biosynthesis. Restricted to gram-positives. Inactivated by surfactant (ineffective for pneumonia).
Marketed as Cubicin/Cubicin RF (approved September 12, 2003). Phase III cSSSI (N=1,092): non-inferior to vancomycin with ~83-84% success. Bacteremia/endocarditis trial (Fowler, NEJM 2006; N=246): non-inferior, 44.2% vs. 41.7%. Renal dysfunction significantly lower (11.0% vs. 26.3%, P=0.004). Pediatric cSSSI (N=389) confirmed efficacy. Indications: cSSSI, S. aureus bloodstream infections including right-sided endocarditis.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Bacitracin is marketed as Baciguent (topical) and BACiiM (injection), and is a component of Neosporin and Polysporin. Approved in 1948, it is one of the oldest peptide antibiotics still in widespread use. Topical bacitracin is available over the counter and is applied to minor cuts, scrapes, and burns to prevent infection. Its systemic use is limited to rare situations where no alternatives exist, due to severe nephrotoxicity. There has been growing discussion in wound care about whether routine topical antibiotic use on minor wounds provides meaningful benefit over simple petroleum jelly in keeping wounds moist, and about the risk of contact allergic dermatitis with repeated bacitracin use.
Comparisons
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
